Key Highlights
- Aspen shares fell 11.32% to close at $12.07 on November 13, 2026.
- The IPO priced at $15.00 per share on October 29, 2026.
- Lead candidate sasineprocel is in a Phase 1/2a trial for Parkinson's disease.
- Phase 3 dosing is expected to begin in the second half of 2027.
Aspen Neuroscience (NASDAQ:ASPE), the San Diego biotech that only recently joined Nasdaq, had a rough Friday. The stock closed at $12.07 on November 13, 2026, down 11.32% for the session, on light volume. With a new listing, a thin trading history can make the share price swing more than usual in either direction.
Fall Without a Clear Catalyst
The company published no announcement for the session, so the fall came against the stock's short trading history and Friday's weak market backdrop.
That history matters. Aspen priced its initial public offering on October 29, 2026, at $15.00 per share, the bottom of its marketed $15 to $17 range. It sold 9,375,000 shares for gross proceeds of about $140.6 million before Underwriting costs, and the stock began trading on the Nasdaq Global Select Market on October 30. The fully diluted Market Value was about $462 million at the IPO price. Five Investment banks acted as joint bookrunners, and the underwriters received a 30-day option to buy up to 1,406,250 more shares. Friday's close leaves the stock about three dollars below the price paid by IPO buyers barely two weeks ago.
Long-Dated Cell Therapy Program
The Business is long-dated by any measure. Aspen is a clinical-stage regenerative medicine company developing autologous cell therapies derived from induced pluripotent stem cells for neurodegenerative disease. Its lead candidate, sasineprocel, is a single-dose therapy made from each patient's own skin-biopsy cells. It is meant to replace the dopamine-producing neurons lost in Parkinson's disease, and the company says it may be disease-modifying. The candidate is being tested in the Phase 1/2a ASPIRO trial in people with mid-stage to moderately advanced sporadic Parkinson's. Fifteen patients had been dosed as of August 18, 2026, and Aspen expects to begin dosing in a Phase 3 trial in the second half of 2027. The program holds Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA.
A pre-revenue company whose next major milestones sit more than a year away is especially exposed to changes in the cost of capital, and Friday offered plenty of that. October producer prices rose 0.3% month over month, below the 0.4% forecast, but were up 6.5% from a year earlier, the biggest 12-month gain since November 2022. The 10-year Treasury Yield was about 5.13% early in the day, and futures pricing showed traders treating a Fed rate rise at the December 8–9 meeting as a near certainty. Higher discount rates weigh hardest on companies valued mostly on cash flows far in the future.
Questions After the IPO Settles
The wider market was mixed. The S&P 500 fell 0.40% to 7,561.67 and the Nasdaq Composite dropped 0.91% to 25,136.27, pulled down by a semiconductor sell-off tied to Leadership turmoil at Nvidia (NASDAQ:NVDA). The Russell 2000 lost 0.31%, while the Dow edged up 0.10%. Many small and mid caps made sharp moves on third-quarter earnings, which kept Volatility high across the smaller end of the market.
For Aspen, the main questions are how the stock trades as the IPO settles and what the company says next about ASPIRO enrollment and its Phase 3 plans.






Please wait processing your request...